Sanofi: positive preclinical evaluation, Covid-19
(CercleFinance.com) - Sanofi Pasteur and Translate Bio, a specialist in messenger RNA (mRNA) therapeutics, announce that the preclinical evaluation of their candidate vaccine, MRT5500, has shown a favourable immune response profile against SARS-CoV-2.
Based on this evaluation, two doses of MRT5500 induced the production of neutralising antibody concentrations significantly higher than those observed in patients infected by the Covid-19 virus.
“These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020” said the two partners.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Based on this evaluation, two doses of MRT5500 induced the production of neutralising antibody concentrations significantly higher than those observed in patients infected by the Covid-19 virus.
“These data support the selection of MRT5500 for clinical development. A Phase 1/2 clinical trial is anticipated to begin in the fourth quarter of 2020” said the two partners.
Copyright (c) 2020 CercleFinance.com. All rights reserved.